AAPG

Dollar change +1.86
Percentage change 5.06	%

Index	-	P/E	-	EPS (ttm)	-0.75	Insider Own	-	Shs Outstand	52.23M	Perf Week	-7.76%
Market Cap	3.36B	Forward P/E	51.24	EPS next Y	0.75	Insider Trans	-	Shs Float	-	Perf Month	22.56%
Enterprise Value	3.42B	PEG	-	EPS next Q	-	Inst Own	0.27%	Short Float	-	Perf Quarter	88.48%
Income	-56.60M	P/S	24.67	EPS this Y	-91.92%	Inst Trans	43.00%	Short Ratio	0.83	Perf Half Y	-
Sales	136.02M	P/B	83.69	EPS next Y	153.22%	ROA	-15.90%	Short Interest	0.01M	Perf YTD	122.21%
Book/sh	0.46	P/C	19.42	EPS next 5Y	34.37%	ROE	-253.16%	52W High	43.58 -11.38%	Perf Year	-
Cash/sh	1.99	P/FCF	-	EPS past 3/5Y	26.85% 36.70%	ROIC	-35.81%	52W Low	16.50 134.06%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	215.77% 130.37%	Gross Margin	88.37%	Volatility	4.41% 4.10%	Perf 5Y	-
Dividend TTM	-	EV/Sales	25.12	EPS Y/Y TTM	59.40%	Oper. Margin	-38.90%	ATR (14)	1.96	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.26	Sales Y/Y TTM	331.22%	Profit Margin	-41.61%	RSI (14)	56.94	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.26	EPS Q/Q	-	SMA20	-0.85%	Beta	-	Target Price	27.00
Payout	-	Debt/Eq	6.43	Sales Q/Q	-	SMA50	23.20%	Rel Volume	0.74	Prev Close	36.76
Employees	567	LT Debt/Eq	3.37	Earnings	Mar 27 BMO	SMA200	56.11%	Avg Volume	16.77K	Price	38.62
IPO	Jan 27, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	12,404	Change	5.06%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-27-25	Initiated	JP Morgan	Overweight

Jul-14-25 11:12AM	Ascentage Pharma's Novel Cancer Drug Approved in China (Insider Monkey) -5.33%
10:35AM	Ascentage Pharma Announces Pricing of Top-Up Placement (GlobeNewswire)
05:23AM	Ascentage Pharma Announces Proposed Top-Up Placement (GlobeNewswire)
Jul-10-25 12:55PM	Ascentage Pharma Announces NMPA Approval for Blood Cancer Drug (Exec Edge)
09:30AM	Ascentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA, Ushering in a New Era for the Treatment of CLL/SLL (GlobeNewswire)
11:58AM	Loading…
Jul-08-25 11:58AM	Ascentage Pharma Names CFO & SVP of Global Corporate Development & Finance (Exec Edge)
Jul-07-25 07:30PM	Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance (GlobeNewswire)
Jun-15-25 07:30PM	EHA 2025 Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL (GlobeNewswire)
Jun-09-25 07:30PM	Thirteen Studies of Ascentage Pharma's Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress (GlobeNewswire) +5.29%
Jun-02-25 07:30PM	Live from ASCO 2025 Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors (GlobeNewswire) +10.03%
07:30PM	Live from ASCO 2025 Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report (GlobeNewswire)
May-22-25 08:15PM	Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025 (GlobeNewswire)
May-11-25 05:20PM	Is Ascentage Pharma (AAPG) the Best Performing Healthcare Stock to Buy Now? (Insider Monkey)
Apr-28-25 07:00AM	Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax (GlobeNewswire)
Apr-23-25 07:00PM	Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin (GlobeNewswire) +10.65% +6.69%
06:10PM	Loading…
Apr-21-25 06:10PM	Ascentage Pharma Drugs Included in Chinese Society of Clinical Oncology Guidelines (Exec Edge) +12.97%
07:00AM	Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines (GlobeNewswire)
Apr-02-25 01:07PM	Stocks To Watch In Gloomy Market Including This Breakout IPO (Investor's Business Daily)
Mar-27-25 07:00AM	Ascentage Pharma Reports Full Year 2024 Unaudited Financial Results and Business Updates (GlobeNewswire) +9.96%
Mar-25-25 07:00PM	Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire)
Mar-12-25 08:46AM	Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025 (GlobeNewswire)
Mar-06-25 05:18PM	Ascentage Secures Third Breakthrough Therapy for Ph+ ALL Treatment (Exec Edge)
Mar-05-25 06:00PM	Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) (GlobeNewswire)
Feb-07-25 08:24AM	Ascentage Pharma Announces Partial Exercise of Underwriters' Option to Purchase Additional American Depositary Shares (GlobeNewswire)
Jan-28-25 04:01PM	Ascentage Pharma Announces Closing of U.S. Initial Public Offering (GlobeNewswire)

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Ascentage Pharma Group International ADR

Upgrade your FINVIZ experience